| |
| |
|
| Insider
Information: |
Dier Mardi |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
101,126 |
|
|
Indirect Shares
|
875 |
|
|
| Direct
Value |
$5,488,828 |
|
|
|
Indirect Value
|
$5,163 |
|
|
| Total
Shares |
102,001 |
|
|
| Total
Value |
$5,493,990 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
1.0
|
| Percentage
Gain/Loss : |
 -71.0%
|
 18.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Portola Pharmaceuticals Inc |
PTLA |
EVP and CFO |
2020-07-02 |
0 |
|
0 |
Premium* |
|
|
Adamas Pharmaceuticals Inc |
ADMS |
Director |
2021-06-02 |
10,000 |
2020-06-03 |
0 |
Premium* |
|
|
Prelude Therapeutics Inc |
PRLD |
Director |
2020-09-29 |
10,000 |
2020-09-29 |
0 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
CFO & Executive Vice P... |
2022-10-14 |
66,695 |
2020-10-12 |
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
CFO and CBO |
2023-05-09 |
5,556 |
2023-05-09 |
875 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-03-11 |
8,875 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2017-06-27 |
4 |
OE |
$7.00 |
$1,736,009 |
D/D |
93,392 |
6,885 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2017-06-27 |
4 |
AS |
$54.94 |
$5,179,825 |
D/D |
(93,392) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
• – – |
2019-04-04 |
4 |
AS |
$37.39 |
$1,513,824 |
D/D |
(40,486) |
66,733 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-10-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
40,000 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP and CFO |
• – – |
2020-07-02 |
4 |
D |
$18.00 |
$712,314 |
D/D |
(39,573) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2017-07-11 |
4 |
AS |
$60.00 |
$1,401,000 |
D/D |
(23,350) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2017-07-11 |
4 |
OE |
$25.08 |
$585,618 |
D/D |
23,350 |
23,350 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
71,808 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
• – – |
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,750 |
116,682 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Interim Co-President & CFO |
• – – |
2018-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
116,271 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Interim Co-President & CFO |
• – – |
2018-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
107,684 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2016-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
16,250 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, CFO & CBO |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
84,968 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-06-08 |
4 |
AS |
$43.00 |
$693,117 |
D/D |
(16,119) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-06-08 |
4 |
OE |
$4.10 |
$69,620 |
D/D |
16,119 |
16,119 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP and CFO |
• – – |
2017-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
15,625 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2016-08-01 |
4 |
OE |
$3.30 |
$50,002 |
D/D |
15,152 |
15,152 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
52,228 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2016-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
13,750 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-05-11 |
4 |
OE |
$7.00 |
$118,596 |
D/D |
13,674 |
13,674 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-05-11 |
4 |
S |
$38.21 |
$522,511 |
D/D |
(13,674) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-05-12 |
4 |
OE |
$9.50 |
$126,255 |
D/D |
13,290 |
13,290 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-05-12 |
4 |
S |
$37.88 |
$503,452 |
D/D |
(13,290) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2018-03-08 |
4 |
D |
$38.69 |
$483,531 |
D/D |
(12,474) |
61,442 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Executive VP and CFO |
• – – |
2015-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
